Al

In this video presentation, the Avacta team discusses the second presentation from this week’s #AACR26 Annual Meeting, our dual payload technology. avacta.wistia.com/medias/xktyxrb… #AVCT

@johnkonrad @ZosoGraffiti @PeteHegseth Historians in the future (if any survive) won’t even know where to begin: “There were warnings… many many warnings… but none as clear as the day ‘which’ became ‘witch’… and no one stopped him.”

We’ve cleaned out Iran’s nukes and drone factories, and gutted their navy. If the Strait reopens without a single U.S. naval casualty… will every Dem here finally admit @PeteHegseth is doing a good job… or just gaslight us again?

A very good point @AM231982 reminded me of. At the #AVCT AGM @coughlin582 said she would like to go after as many indications as possible with AVA6103, but conceded this would likely be 2 given the expense. @avacta has opted for x4 indications. Tells you all you need to know.

It’s been highly impressive to watch the speed at which @coughlin582 and her team have expedited AVA6103 and AVA6207 since I joined the board of #AVCT a little over 6 months ago. The pre|CISION technology which sits behind these drugs is nothing short of groundbreaking.

Pazdur Onboard: What It Means for Avacta In the corridors of the FDA, a familiar name has taken over as Director. Richard Pazdur, long regarded as the architect of modern oncology regulation, now leads the CDER (Center for Drug Evaluation and Research), the nerve center of America’s prescription drug oversight. Pazdur’s fingerprints are everywhere in cancer drug policy. He is the founding mind behind the Oncology Center of Excellence and Project Orbis, the mechanism that allows companies to submit oncology drugs for simultaneous review across multiple global regulators. The FDA’s oncology czar has just taken command of the agency’s entire drug approval empire. Pazdur understands mechanism driven oncology better than anyone in the building. His philosophy favors mechanism based drugs because he’s spent decades seeing that therapies grounded in solid biology often deliver real clinical benefit faster than traditional, data heavy programs. He knows that in oncology, strong mechanistic rationale and early proof of target engagement can be more predictive of success than waiting years for large survival datasets, which is why he built frameworks like Accelerated Approval and Project Orbis: for scientifically coherent drugs to reach patients, and the market, sooner. Since our #AVCT’s molecular trojan horse Ava6000 does not fit the old template, it requires regulators who understand innovation at the mechanistic level. Under a less visionary director, small biotechs risk being lost in procedural purgatory. Under Pazdur, the FDA becomes fluent in the language of mechanism. There’s also a geopolitical dimension. Pazdur’s Orbis network built bridges between the FDA, MHRA, and EMA; precisely the triad on which AVCT’s UK to US ambitions depend. That framework could open a cleaner passage for cross border submissions and earlier recognition of efficacy easing the long delay that so often punishes UK innovation. The FDA’s top office is now led by someone who has spent his career championing oncology’s true innovators, the ones advancing chemistry and biology to change patient outcomes @coughlin582 🫡 His early support for checkpoint inhibitors like Keytruda and Opdivo proved how quickly he’ll back sound science when the biology is clear. Pazdur’s FDA is all ears fda.gov/news-events/pr…

pre|CISION PDCs are so far ahead of ADCs in pretty much every aspect that - evidently - for the large majority of market participants, the story is quite simply unbelievable. The investment proposition for buying #AVCT shares now is that the international investment community rarely bothers to look at LSE-listed stocks outside of the FTSE100. @avacta will be one of those rare exceptions, soon enough. The ex-UK community will not simply sit on the sidelines and watch whilst the owner of the most disruptive technology in the oncology industry in decades builds its IP moat and pipeline as an independent. Said industry will be generating sales of >$400bn per annum by the end of this decade. The upside for the ultimate owner of the pre|CISION platform is immense. For a £300m mkt cap business, it is for all intents and purposes, unlimited.

@JohnnyFinnie Thanks, very kind of you.. I’ll just keep other factors to myself.. 🌚

@Allie_aa_ I did see that, helps a bit. Extensive knowledge and understanding very impressive if I’m honest. Thanks for sharing 👏👌🕺

Pricing Olympics Watching people trying to price in preCISION right now.. If you don’t sound slightly insane explaining it and if you don’t catch that polite but panicked smile “but I have no idea what you just said” stare you probably don’t understand it yet. Because shifts like this rarely follow linear adoption curves: • Mechanistic evidence emerges before valuation models know how to parameterise it • Clinical confidence lags because replication takes time, not belief • Legacy oncology frameworks treat new chemistry as outliers until the data demand reclassification • Regulators accelerate when therapeutic biology eliminates optionality; once a mechanism proves superiority, frameworks adapt to it Every breakthrough starts as heresy, then becomes inevitability, then settles as orthodoxy. Markets still expect cancer drugs to behave like… cancer drugs. Meanwhile Avacta just rewrote tumour activation into the next era, and the models are reacting like Horse staring at Tesla.. History runs this movie on loop: mRNA, RNAi, CRISPR, GPUs, Cloud. Before the math adjusts, the narrative doesn’t fit. Before the narrative fits, the crowd rejects it. And before the crowd believes… the quiet money is already seated. Markets are never on time, they move all at once. Disbelief, then instant revaluation, as if doubt had never existed. And here’s the awkward bit: If preCISION works across solid tumours as the mechanism suggests, the question isn’t whether the valuation goes higher, it’s whether current pricing frameworks are even capable of containing where it lands? Some technologies don’t rerate.. they can only get reclassed. In biotech, breakthroughs always pass through ‘the delusional phase’ just before they graduate into doctrine. Until then, go forth, and bear thy glorious madness with pride; for all great truths are treason right up until it becomes a very, very large rerate.. 🦛

@RAH00084 Now think, if the evidence is strong enough to support this then it must also support the view that many other payloads could be similarly delivered. No point in trying to put numbers here, it's totally off the scale.

Thanks, it is… there was an era when “pretend longterm” voices and emotion hunters ruled the field.. stirring hype charts, false booms leaving true investors scarred with marketPTSD. Not great for the cause. Glad we’re at the ‘seismic shift,’ as you put it, and glad to be, in a small way, undoing some of that now..

@Allie_aa_ Hi Allie, I love your posts.. trying to value new ground breaking technology. Akin to an Earthquake ... tremor.. then a seismic shift .. quite dramatic really .. old buildings tumble .. new ones are born. A new landscape to look. I can't wait.

@JohnnyFinnie Updated my bio

@Allie_aa_ I obviously agree with that statement. Can I ask what is your background? Thanks 🙏🏻

It is straightforward to watch yesterday's presentation by @avacta #AVCT and understand that it is making truly revolutionary advances in oncology. I am more convinced than ever that the pre|CISION platform's peptide-drug conjugates will largely displace antibody-drug conjugates and go on to dominate the >$350bn per annum global oncology market for decades to come. We are only 4 months into what I believe will be one of the all-time great turnarounds for an LSE-listed stock. Avacta's share price is (only!) +135% in that period - but the picture is becoming clearer for many now. Expecting daily volumes to continue to increase and the SP to challenge 100p before Christmas, regardless of any commercial news flow. That said, I really think Big Pharma will make a move soon, whether that's for an initial licensing deal or an outright takeover attempt.

@royaldaring I dare say, #AVCT seems to have cornered both the 𝑫𝒂𝒓𝒊𝒏𝒈 and the 𝑰𝒏𝒔𝒊𝒈𝒉𝒕𝒔 this week.. 😁

@Allie_aa_ Inspring write up

RNSs The Architecture Expands Now that the Boston data have landed, the picture is clearer. #AVCT’s dual payload preCISION system delivers the logical proof of concept that the apart of the platform being repurposable; it’s programmable. The roots were planted to grow in every direction. What began as a tumour activated delivery mechanism has evolved into a two channel engine capable of synchronised release, independent targeting, and fully tunable kinetics. A subtle but profound leap transforms preCISION from a platform into an adaptive therapeutic construct. •The Data: Confirmed: simultaneous dual payload release from a single enzymatic event; one cut, two drugs. 4-5× higher tumour killing potency versus single agent exatecan in resistant models. Dual mechanisms firing (exatecan with PARP or MMAE) with biomarkers lighting up precisely where FAP is present, remaining silent where it’s not. Even FAPnegative cells collapse once their neighbours trigger the switch. A mechanistic print of an adaptable delivery system. •The Broader Implication Dual payload therapeutics are oncology’s holy grail; two mechanisms, one molecule, one cut. They’ve been tried before, but biology and manufacturing always stood in the way of clean synchrony. #AVCT’s chemistry first approach has achieved what antibodies couldn’t. That changes everything from dosing logic to regulatory framing. It means the FDA can now treat preCISION as a programmable platform. Once replication is shown clinically, every future variant can move through extension pathways, rather than full Phase 1 resets. It’s the same inflection that lifted RNAi, mRNA, and ADC frameworks. •Investor and Pharma Lens For investors, this is the architectural proof that the platform is adaptive. For Pharma, it’s the rare intersection of control, breadth, and safety. To a business development team, that reads like a drop in upgrade for any oncology pipeline: no need for biologic infrastructure, or to rebuild supply chains just plug the chemistry into existing assets. Where We Go From Here Investor Meet (Oct 29): Expect linkage of preclinical AVA6207 findings with ongoing AVA6000/6103 clinical paths a unified platform roadmap. Regulatory traction: Dual payload data directly address resistance, a core Fast Track and Orphan expansion criterion. Strategic approach: Historically, this is when data rooms open and exploratory NDAs start moving through legal. Financing architecture: The latest RNS outlines amendments to the convertible bond and an equity raise designed to extend runway into key catalysts. The structure tightens liquidity, reduces near term uncertainty, and positions Avacta to negotiate partnerships from strength. •Capital alignment: With the science now validated and the balance sheet stabilised, the next pivot is turning data into deals, and proof into partnership.. Strategic capital, co-development, or platform licensing become the natural levers to monetise proof of concept. And judging by management’s discipline, the era of funding for survival has given way to funding for leverage, growth and expansion. ⬇️ ⬇️

Part2 •The Meta Shift The rerate starts to brew the moment the data and funding structure enter the models watched by Big Pharma and institutional algorithms. First it was GlobeNewswire, then Yahoo Finance, Morningstar, Apple Stocks, FT, and Proactive. To the untrained eye, it looks like coverage but it’s not. It’s indexing. Once an RNS hits those pipes, it becomes code; structured, machine readable, fund searchable, model grade input. That information flows into sentiment engines, quant dashboards, and algorithmic filters that tell capital what’s worth watching. Now the narrative has both sides of the equation: Scientific validation (Boston data). Financial stability (convertible restructuring + equity raise). What this means: When outlets like Yahoo Finance, Morningstar, FT, Proactive and others combine R&D breakthroughs with capital structure improvements, they go beyond headlines; they mark the point where institutional recognition starts to take shape reflecting both visibility and investment utility. The science gives it credibility; the funding gives it runway. Together, they form a narrative that investors and algorithms recognise as a platform emerging from discovery into deployment. Keywords (FAPactivated, dual payload, resistance, synergy, extended runway) gets parsed, scored, and mapped into oncology innovation models. Once tagged in the right clusters (Oncology Innovation, Platform Therapeutics, NextGen Delivery), #AVCT starts appearing beside Moderna, Alnylam, Seagen in institutional screens. That visibility becomes value. Because the rerate starts forming the moment the machines begin rewriting their assumptions.. long before the market catches up.

@Ruthyrururu Most welcome 🙏🏻

@Allie_aa_ Excellent post thank you.

The Moment We All Brace Dr. Christina Coughlin confirmed what the close watchers already sensed #AVCT’s Therapeutics Division will present its published data from the first ever dual payload pre|CISION peptide drug conjugate system, fresh from the AACR–NCI–EORTC Molecular Targets Congress in Boston. The meeting itself is jointly organised by three of the field’s most powerful scientific bodies: • #AACR the American Association for Cancer Research • #NCI the National Cancer Institute, the U.S. government’s flagship cancer research arm • #EORTC the European Organisation for Research and Treatment of Cancer Curators of the Molecular Targets meeting; where biotech and pharma unveil the preclinical and translational breakthroughs that shape the next generation of cancer drugs. But unlike #ESMO or #ASCO (equal parts medicine and market theatre) AACR–NCI–EORTC is a laboratory with microphones, where mechanistic data meets interrogation from the same minds who advise the FDA and sit on Big Pharma diligence committees. It’s an entry into the scientific bloodstream; the Sloan Kettering, MD Anderson, and Dana Farber circuit that decides how oncology moves. It’s where principal investigators overlap with FDA advisers, trial architects double as pharma scouts, and every data slide becomes a pipeline discussion. These are the institutions that design early trials. Their clinicians chair ODAC panels, sit on programme boards, and hold advisory roles across AstraZeneca, BMS, Novartis, and Merck’s translational units. When your molecule is dissected in that room, you’re briefing the people shaping tomorrow’s oncology era, a validation level small cap biotechs rarely touch, and scientific acknowledgement from the gatekeepers of both regulation and capital. History leaves a trail: • When ImmunoGen first revealed its ADC linker chemistry here, Roche and Sanofi began the exchanges that would lead to billion dollar licensing, ultimately a $10B AbbVie acquisition. • Alnylam used this same stage to prove its RNAi engine could adapt across diseases, the turning point that transformed RNA therapeutics and built a $25B franchise. • And long before Moderna was a household name, its early mRNA delivery data debuted here, sparking the partnerships that later built a $100B biotech empire. So when Avacta’s dual payload preCISION data appears on this stage, it’s an invitation into the professional conversation that decides what becomes the next oncology backbone. Most companies reach this level of peer review only once their pivotal trials are nearly complete and replication is already baked in. #AVCT, by contrast, arrives midPhase 1b with human safety, tolerability, and efficacy already in hand and knows exactly what it’s holding. The data that has NCI collaborations and pharma’s business development teams waiting for permission to pounce. It’s rare air for a company of Avacta’s size. At this tier, small caps usually attend and leave presenting to the giants. Yet preCISION now sits alongside ADCs, radioligands, and other flagship modalities, the shift from promising chemistry to platform of record. Behold the rerate taking shape. And unlike the figures above, Avacta’s ceiling sits somewhere north of that..🚀

@JohnnyFinnie Thanks a ton, Johnny really kind words, and much appreciated

@Allie_aa_ Very very intuitive a masterpiece of dialogue and review. A revelation , well written and well done 🙏🏻🤙